Table II.
Results of the univariate analyses to determine factors predictive of OS.
| Clinicopathological characteristic | N | No. of mortalities | 1-year OS (95% CI) | 2-year OS (95% CI) | 5-year OS (95% CI) | P-value (log-rank) |
|---|---|---|---|---|---|---|
| All patients | 110 | 44 | 90.7 (83.3–94.9) | 80.0 (71.0–86.5) | 66.0 (55.9–74.3) | |
| Age, years | 0.003 | |||||
| ≤50 | 39 | 8 | 94.8 (80.8–98.7) | 89.4 (74.1–95.9) | 80.9 (64.0–90.4) | |
| >50 | 71 | 36 | 88.3 (77.9–94.0) | 74.6 (62.3–83.4) | 57.6 (44.7–68.5) | |
| Gender | 0.267 | |||||
| Female | 57 | 25 | 87.1 (74.8–93.6) | 75.6 (61.7–85.1) | 59.5 (44.8–71.5) | |
| Male | 53 | 19 | 94.3 (83.5–98.1) | 84.5 (71.4–91.9) | 72.5 (58.0–82.7) | |
| Tumor size, cm | 0.022 | |||||
| ≤5 | 37 | 10 | 94.6 (80.1–98.6) | 89.2 (73.7–95.8) | 80.5 (63.3–90.2) | |
| >5 | 73 | 34 | 88.6 (78.5–94.1) | 75.0 (62.8–83.7) | 58.0 (45.2–68.8) | |
| Tumor depth | 0.098 | |||||
| Epifascial | 52 | 18 | 96.0 (85.1–99.0) | 86.0 (72.9–93.1) | 75.6 (60.9–85.3) | |
| Subfascial | 58 | 26 | 85.9 (73.8–92.7) | 74.6 (60.8–84.1) | 57.3 (43.0–69.3) | |
| Grading | 0.003a | |||||
| G1 | 32 | 7 | 100 (−) | 100 (−) | 88.9 (69.3–96.3) | |
| G2 | 32 | 13 | 87.5 (70.0–95.1) | 84.3 (66.2–93.1) | 64.0 (44.4–78.3) | |
| G3 | 46 | 24 | 86.3 (72.0–93.6) | 62.3 (46.0–75.0) | 50.3 (34.5–64.2) | |
| Subtype | ||||||
| NOS | 31 | 18 | 64.5 (45.2–78.5) | 57.9 (38.7–73.0) | 57.9 (38.7–73.0) | 0.166 |
| Angiosarcoma | 21 | 17 | 73.7 (47.9–88.1) | 57.9 (33.2–76.3) | 26.3 (9.6–46.8) | <0.001 |
| Liposarcoma | 19 | 4 | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 88.1 (60.2–96.9) | 0.007 |
| Leiomyosarcoma | 10 | 4 | 80.0 (40.9–94.6) | 80.0 (40.9–94.6) | 66.7 (27.2–88.1) | 0.361 |
| Margin status (Primary tumor) | 0.046 | |||||
| R0 | 96 | 36 | 92.5 (85.0–96.4) | 82.6 (73.1–88.9) | 69.9 (59.2–78.3) | |
| R1/R2 | 14 | 8 | 76.9 (44.2–91.9) | 61.5 (30.8–81.8) | 38.5 (14.1–62.8) | |
| Full-thickness resection | 0.025 | |||||
| No | 89 | 32 | 96.5 (89.6–98.9) | 84.5 (74.7–90.7) | 70.7 (59.5–79.3) | |
| Yes | 21 | 12 | 66.7 (42.5–82.5) | 61.9 (38.1–78.8) | 46.4 (24.4–65.9) | |
| Wound closure | 0.352 | |||||
| Primary closure | 90 | 35 | 94.3 (86.9–97.6) | 82.5 (72.7–89.1) | 68.0 (56.9–76.9) | |
| Plastic surgical tissue transfer | 20 | 9 | 73.7 (47.9–88.1) | 68.4 (42.8–84.4) | 55.8 (30.2–75.2) | |
| Adjuvant radiotherapy received (Primary tumor) | 0.383 | |||||
| No | 73 | 27 | 90.0 (80.2–95.1) | 79.8 (68.3–87.5) | 70.5 (58.0–79.9) | |
| Yes | 37 | 17 | 91.9 (76.9–97.3) | 80.4 (63.2–90.2) | 57.4 (39.6–71.8) | |
| Adjuvant chemotherapy received (Primary tumor) | 0.479 | |||||
| No | 96 | 37 | 89.3 (81.0–94.1) | 80.4 (70.7–87.2) | 66.6 (55.7–75.3) | |
| Yes | 14 | 7 | 100 (−) | 76.9 (44.2–91.9) | 61.5 (30.8–81.8) |
a
Global log-rank test for trend of survivor functions. OS, overall survival; CI, confidence interval; NOS, sarcoma not otherwise specified.